Vitamin e and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 21, Issue 4, 2010, Pages 1383-1392

  Iuliano, Luigi ^a   Monticolo, Roberto ^a   Straface, Giuseppe ^a   Spoletini, Ilaria ^b   Gianni, Walter ^c   Caltagirone, Carlo ^b,d   Bossù, Paola ^b   Spalletta, Gianfranco ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c INRCA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alzheimer's disease; amnestic; cholesterol; mild cognitive impairment; oxysterols; vitamin E

Indexed keywords

24S HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; 7 OXOCHOLESTEROL; 7BETA HYDROXYCHOLESTEROL; ALPHA TOCOPHEROL; CHOLESTEROL DERIVATIVE; ISOTOPE; OXYSTEROL; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; ISOTOPE DILUTION ASSAY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION;

EID: 78650475565     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100780     Document Type: Article

References (58)

1. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314, 777-781.
2. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
3. Shobab LA, Hsiung GY, Feldman HH (2005) Cholesterol in Alzheimer's disease. Lancet Neurol 4, 841-852.
4. Wolozin B (2001) A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci USA 98, 5371-5373.
5. Nelson TJ, Alkon DL (2005) Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans 33, 1033-1036.
6. Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S (2009) Oxysterols and neurodegenerative diseases. Mol Aspects Med 30, 171-179.
7. Marx J (2001) Alzheimer's disease. Bad for the heart, bad for the mind? Science 294, 508-509.
8. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58, 397-405. (Pubitemid 32217456)
9. Markesbery WR (1999) The role of oxidative stress in Alzheimer disease. Arch Neurol 56, 1449-1452.
10. Nelson TJ, Alkon DL (2005) Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 280, 7377-7387.
11. Mitomo H, Chen WH, Regen SL (2009) Oxysterol-induced rearrangement of the liquid-ordered phase: a possible link to Alzheimer's disease? J Am Chem Soc 131, 12354-12357.
12. Kim DH, Frangos JA (2008) Effects of amyloid beta-peptides on the lysis tension of lipid bilayer vesicles containing oxys-terols. Biophys J 95, 620-628.
13. Zhang Q, Powers ET, Nieva J, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P, Jr., Lerner RA, Kelly JW (2004) Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci USA 101, 4752-4757.
14. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Bjorkhem I (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 93, 9799-9804.
15. Pratico D (2008) Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 29,609-615.
16. Micheletta F, Iuliano L (2006) Free radical attack on cholesterol: oxysterols as markers of oxidative stress and as bioac-tive molecules. Immun Endoc Metab Agents in Med Chem 6, 305-316.
17. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33, 1152-1162.
18. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 27, 262-269. (Pubitemid 43038550)
19. Ricciarelli R, Argellati F, Pronzato MA, Domenicotti C (2007) Vitamin E and neurodegenerative diseases. Mol Aspects Med 28, 591-606.
20. Grundman M (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 71, 630S-636S.
21. Wengreen HJ, Munger RG, Corcoran CD, Zandi P, Hayden KM, Fotuhi M, Skoog I, Norton MC, Tschanz J, Breitner JC, Welsh-Bohmer KA (2007) Antioxidant intake and cognitive function of elderly men and women: the Cache County Study. JNutr Health Aging 11, 230-237.
22. Isaac MG, Quinn R, Tabet N (2008) Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database SystRev, CD002854.
23. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
24. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412-2414.
25. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erk-injuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report ofthe NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
27. Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iu-liano L (2007) Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radic Biol Med 42, 698-705.
28. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 12, 189-198.
29. Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36, 378-384.
30. Rey A (1941) L'examen psychologique dan les cas d'encephalopathie traumatique (les problemes). Arch Psy-chologique 28, 286-340.
31. Osterrieth P (1944) le test de copie d'une figure complexe. Arch Psychologique 30, 206-356.
32. Scoop J (1935) Studies of interference in serial verbal reactions. JExperim Psycol 18, 643-662.
33. Dzeletovic S, Breuer O, Lund E, Diczfalusy U (1995) Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 225, 73-80.
34. Iuliano L, Micheletta F, Natoli S, Ginanni Corradini S, Iappelli M, Elisei W, Giovannelli L, Violi F, Diczfalusy U (2003) Measurement of oxysterols and alpha-tocopherol in plasma and tissue samples as indices of oxidant stress status. Anal Biochem 312, 217-223.
35. Liebler DC, Burr JA, Philips L, Ham AJ (1996) Gas chromatography-mass spectrometry analysis of vitamin E and its oxidation products. Anal Biochem 236, 27-34.
36. Larsson H, Bottiger Y, Iuliano L, Diczfalusy U (2007) In vivo interconversion of 7beta-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress. Free Radic Biol Med 43, 695-701.
37. Traber MG, Jialal I (2000) Measurement of lipid-soluble vitamins -further adjustment needed? Lancet 355, 2013-2014.
38. Iuliano L, Monticolo R, Straface G, Zullo S, Galli F, Boaz M, Quattrucci S (2009) Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am J Clin Nutr 90, 477-484.
39. Zieden B, Kaminskas A, Kristenson M, Kucinskiene Z, Vessby B, Olsson AG, Diczfalusy U (1999) Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Arterioscler Thromb VascBiol 19, 967-971.
40. Alkazemi D, Egeland G, Vaya J, Meltzer S, Kubow S (2008) Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J Clin Endocrinol Metab 93, 4282-4289.
41. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27, 394-401.
42. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M (1986) The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 23(Pt 5), 514-520.
43. Kolsch H, Heun R, Kerksiek A, Bergmann KV, Maier W, Lutjohann D (2004) Altered levels of plasma 24S-and 27-hydroxycholesterol in demented patients. Neurosci Lett 368, 303-308.
44. Lund EG, Guileyardo JM, Russell DW (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96, 7238-7243.
45. Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Bjorkhem I (2003) Side chain oxidized oxysterols in cere-brospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res 44, 793-799.
46. Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46, 10471052.
47. Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U (2006) Oxysterols and Alzheimer's disease. Acta Neurol Scand Suppl 185, 43-49.
48. Famer D, Meaney S, Mousavi M, Nordberg A, Bjorkhem I, Crisby M (2007) Regulation of alpha-and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 359, 46-50.
49. Mateos L, Akterin S, Gil-Bea FJ, Spulber S, Rahman A, Bjorkhem I, Schultzberg M, Flores-Morales A, Cedazo-Minguez A (2009) Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol 19, 69-80.
50. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, Heun R (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41, 195-198.
51. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Bjorkhem I (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 45, 186-193.
52. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42, 186-191.
53. Bretillon L, Siden A, Wahlund LO, Lutjohann D, Minthon L, Crisby M, Hillert J, Groth CG, Diczfalusy U, Bjorkhem I (2000) Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 293, 87-90.
54. Solomon A, Leoni V, Kivipelto M, Besga A, Oksengard AR, Julin P, Svensson L, Wahlund LO, Andreasen N, Winblad B, Soininen H, Bjorkhem I (2009) Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci Lett 462, 89-93.
55. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, von Bergmann K, Heun R (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36, 27-32.
56. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Bjorkhem I, von Bergmann K, Heun R (2000) Plasma 24S- hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 11, 1959-1962.
57. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: mi-croarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101, 2173-2178.
58. Meaney S, Heverin M, Panzenboeck U, Ekstrom L, Axels-son M, Andersson U, Diczfalusy U, Pikuleva I, Wahren J, Sattler W, Bjorkhem I (2007) Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res 48, 944-951